Iterum Therapeutics plc (ITRMF) Retained Earnings (2017 - 2025)

Iterum Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at $498.6 million for Q3 2025.

• In Q3 2025, Retained Earnings rose 203.98% year-over-year to $498.6 million; the TTM figure through Sep 2025 stood at $498.6 million (up 203.98% YoY), while the FY2024 annual figure was $481.7 million, up 48167500.0% from the prior year.
• Retained Earnings for Q3 2025 stood at $498.6 million, up from $493.2 million in the prior quarter.
• The five-year high for Retained Earnings was $498.6 million in Q3 2025, with the low at -$479.5 million in Q3 2024.
• The 5-year median for Retained Earnings is -$378.5 million (2021), against an average of -$160.4 million.
• Peak annual rise in Retained Earnings reached 48167500.0% in 2024, while the deepest fall reached 1820653.85% in 2024.
• Iterum Therapeutics' Retained Earnings stood at -$378.5 million in 2021, then jumped by 99.91% to -$350000.0 in 2022, then jumped by 100.29% to $1000.0 in 2023, then jumped by 48167500.0% to $481.7 million in 2024, then climbed by 3.51% to $498.6 million in 2025.
• Business Quant data shows ITRMF's Retained Earnings at $498.6 million in Q3 2025, $493.2 million in Q2 2025, and $488.1 million in Q1 2025.